Cancer cell fusion: a potential target to tackle drug-resistant and metastatic cancer cells.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
28
02
2019
revised:
22
04
2019
accepted:
28
05
2019
pubmed:
5
6
2019
medline:
12
6
2020
entrez:
5
6
2019
Statut:
ppublish
Résumé
Cell fusion is an integral, established phenomenon underlying various physiological processes in the cell cycle. Although research in cancer metastasis has hypothesised numerous molecular mechanisms and signalling pathways responsible for invasion and metastasis, the origin and progression of metastatic cells within primary tumours remains unclear. Recently, the role of cancer cell fusion in cancer metastasis and development of multidrug resistance (MDR) in tumours has gained prominence. However, evidence remains lacking to justify the role of cell fusion in cancer metastasis and drug resistance. Here, we highlight plausible mechanisms governing cell fusion with different cell types in the tumour microenvironment (TME), the clinical relevance of cancer cell fusion, its potential as a target for overcoming MDR and inhibiting metastasis, and putative modes of treatment.
Identifiants
pubmed: 31163272
pii: S1359-6446(19)30041-8
doi: 10.1016/j.drudis.2019.05.024
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1836-1844Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.